Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review.
Kalincik T.
Neuroepidemiology. 2015;44(4):199-214. doi: 10.1159/000382130. Epub 2015 May 20.
[Relapsing-Remitting Multiple Sclerosis].
Niino M, Miyazaki Y.
Brain Nerve. 2021 May;73(5):442-449. doi: 10.11477/mf.1416201784.
Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.
Vidal-Jordana A, Sastre-Garriga J, Rovira A, Montalban X.
J Neurol. 2015 Dec;262(12):2617-26. doi: 10.1007/s00415-015-7798-0. Epub 2015 Jun 5.
Systematic review of prediction models in relapsing remitting multiple sclerosis.
Brown FS, Glasmacher SA, Kearns PKA, MacDougall N, Hunt D, Connick P, Chandran S.
PLoS One. 2020 May 26;15(5):e0233575. doi: 10.1371/journal.pone.0233575. eCollection 2020.
Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis.
Yong HYF, Yong VW.
Nat Rev Neurol. 2022 Jan;18(1):40-55. doi: 10.1038/s41582-021-00581-x. Epub 2021 Nov 3.
Screening of dysphagia in relapsing-remitting multiple sclerosis patients in Montenegro.
Eraković JL, Radulović LB, Idrizović ZA, Roganović MB.
Neurosciences (Riyadh). 2021 Oct;26(4):331-338. doi: 10.17712/nsj.2021.4.20210063.
Executive functions in relapsing-remitting multiple sclerosis.
Elosúa MR, Villadangos N.
Appl Neuropsychol Adult. 2025 Jul-Aug;32(4):944-952. doi: 10.1080/23279095.2023.2252125. Epub 2023 Nov 6.
Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.
Hu Y, Nie H, Yu HH, Qin C, Wu LJ, Tang ZP, Tian DS.
Autoimmun Rev. 2019 May;18(5):542-548. doi: 10.1016/j.autrev.2019.03.011. Epub 2019 Mar 4.
Moyamoya masquerading as relapsing remitting multiple sclerosis.
Feldman S, Esch M, Saidha S.
Neurol Sci. 2019 Mar;40(3):635-637. doi: 10.1007/s10072-018-3615-8. Epub 2018 Oct 27.
Advances in the treatment of relapsing-remitting multiple sclerosis.
Tanasescu R, Ionete C, Chou IJ, Constantinescu CS.
Biomed J. 2014 Mar-Apr;37(2):41-9. doi: 10.4103/2319-4170.130440.
